To assess hematologic and nonhematologic toxicity of chlorambucil (CLB) when combined with escalating doses of 2-chlorodeoxyadenosine (2-CDA) in patients with chronic lymphoid leukemias and low-grade lymphomas. To obtain pharmacokinetic data during infusion of 2-CDA combined with CLB and to monitor tumor response.
|Effective start/end date||10/1/92 → 9/30/94|
- National Center for Research Resources
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.